Obesity Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Study of Effects of Two Fixed-dose Leucine-sildenafil Combinations (NS-0300) or Two Fixed-dose Leucine-sildenafil-metformin Combinations (NS-0200) Versus Placebo on Body Weight in Obesity
Verified date | November 2018 |
Source | NuSirt Biopharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a 24-week study to evaluate the effects of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo. The primary objective of this study is to evaluate the percentage change in body weight in subjects from Baseline/Visit 2 (Day 1) to Study Termination/Visit 8 (Day 168/Week 24).
Status | Completed |
Enrollment | 267 |
Est. completion date | August 17, 2018 |
Est. primary completion date | August 6, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Age =18 and =65 at study entry. 2. Is male, or female and, if female, meets all of the following criteria: 1. Not breastfeeding 2. Post-menopausal or negative serum pregnancy test result (human chorionic gonadotropin, beta subunit [ß-hCG]) at Screening/Visit 1 (Day-7/Week-1) (not required for hysterectomized females) 3. If of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods [male condom with spermicide, with or without cervical cap or diaphragm], implants, injectables, oral contraceptives [must have been using for at least the last 3 months], some intrauterine contraceptive devices, tubal ligation, or in an established relationship with a vasectomized or same sex partner) during the entire duration of the study 3. Stable body weight (±5%) and health over the last 3 months. 4. Has a BMI between 30 kg/m2 and 45 kg/m2 5. Stable diet within the last three months 6. Subjects on antidepressants, excluding those listed in the exclusion criteria, must have been on a stable dose regiment for at least 3 months prior to study enrollment and maintain stable dose during the study 7. Clinical laboratory tests (hematology, clinical chemistry, and urinalysis) either normal, not clinically significant or with abnormalities consistent with obesity 8. Is able to read, understand, and sign the informed consent forms (ICF) and, when applicable, an authorization to use and disclose protected health information form (consistent with Health Insurance Portability and Accountability Act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements. Exclusion Criteria: 1. Diagnosis of diabetes or on a diabetes medication 2. HbA1c =6.5% at Screening/Visit 1 (Day-7/Week-1) 3. Severe renal impairment (eGFR < 45 mg/mL/1.73 m2) and/or patients with acute or chronic metabolic acidosis. Acidosis is defined as >25mmol/L computed without K. Normal is 8- 16, but acidosis is >25 4. Use of any of the following medications in the eight weeks prior to entering screening for study participation and during the study: 1. Use of any anti-diabetes medication including metformin and any combination drug that contains metformin 2. Sildenafil 3. Tadalafil 4. Vardenafil 5. OCT2/MATE inhibitors (e.g. cimetidine, quinidine, and pyrimethamine) 6. Riociguat (guanylate cyclase stimulant) 7. Alpha blockers 8. Nitrates (e.g. oral nitrates, sublingual nitroglycerine and nitroglycerine patches) 9. Potent CYP3A4 inhibitors (e.g. clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir) 10. All antihypertensive medications 11. Medications associated with weight changes - Drugs approved for the treatment of obesity - Cypropheptadine or medroxyprogesterone - Atypical anti-psychotic drugs - Tricyclic antidepressants - Lithium, MAO's, glucocorticoids - SSRI's or SNRI's - Antiepileptic drugs - Systemic corticosteroids - Stimulants e.g. amphetamines 12. Any dietary supplement that is labeled for weight management or maintenance of healthy weight 5. Diagnosis or evidence of eating disorders 6. = 5% weight change in the last 3 months 7. Subjects who have had bariatric surgery 8. An infection requiring antibiotic treatment within the last 30 days 9. Any chronic inflammatory disease, e.g. inflammatory bowel disease rheumatoid arthritis, vasculitis, systemic lupus erythematosus 10. Diseases interfering with metabolism (including metabolism of branched chain amino acids) and/or ingestive behavior (myxedema, Cushing's disease, diabetes, schizophrenia, major psychoses, maple syrup urine disease, unmanaged depression etc.) 11. History of alcohol abuse (defined = 21 drinks per week for males and > 14 drinks per week for females), within the past 3 months or failure on urinary drug screen 12. History of substance abuse (including alcohol abuse as defined above) in the past 12 months or a positive screen for drugs (opioids without a prescription), including marijuana, of abuse or alcohol at screening. 13. Has received any investigational drug within 3 months of Screening. 14. Has donated blood within 3 months before Screening or is planning to donate blood during the study (due to HbA1c reading at screening) 15. Other medical conditions that may diminish life expectancy to <2 years, including known cancers 16. Have been diagnosed with metastatic carcinomas in the last 5 years 17. Has known allergies or hypersensitivity to metformin, sildenafil or leucine 18. Have suffered myocardial infarction, stroke, arrhythmia in the last 6 months 19. Resting hypotension (BP <90/50 mmHg) or severe hypertension (BP >170/110 mmHg) If both or one of the parameters for diastolic or systolic BP is meet 20. Cardiac failure or coronary artery disease causing unstable angina 21. History or evidence at screening of left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure 22. At risk for priapism due to anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, Peyronie's disease) or other conditions that predispose to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia) 23. Clinical evidence of hepatic impairment and/or ALT/AST >5X ULN 24. Is an immediate family member (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the clinical study site, or NuSirt Biopharma. 25. Is employed by NuSirt Biopharma (defined as an employee, temporary contract worker, or designee responsible for the conduct of the study). |
Country | Name | City | State |
---|---|---|---|
United States | Pennington Biomedical Research Center | Baton Rouge | Louisiana |
United States | Medical Research South | Charleston | South Carolina |
United States | Synexus | Chicago | Illinois |
United States | Premier | Clarksville | Tennessee |
United States | Rapid Medical Research | Cleveland | Ohio |
United States | Synexus | Dallas | Texas |
United States | ACR | Jordan | Utah |
United States | AMR | Las Vegas | Nevada |
United States | ACR | Meridian | Idaho |
United States | Clinical Trials Management | Metairie | Louisiana |
United States | AMR | Mobile | Alabama |
United States | Catalina Research Institute | Montclair | California |
United States | Northern California Research | Sacramento | California |
United States | Synexus | Saint Louis | Missouri |
United States | Synexus | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
NuSirt Biopharma |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage Body Weight Change | The percentage body weight change from baseline to Day 168 was evaluated. | Baseline to Day 168 | |
Secondary | Change in Absolute Body Weight | The change in absolute body weight from baseline to day 168 was evaluated. | Baseline to Day 168 | |
Secondary | Change in Percentage of Patients With =5% Body Weight Loss | The number of patients with =5% body weight loss in each group was assessed from baseline to day 168. | Baseline to Day 168 | |
Secondary | Change in Waist Circumference | The change in waist circumference by using a tape measure across the mid-section was evaluated in subjects from baseline to day 168. | Baseline to Day 168 | |
Secondary | Change in Total Cholesterol | Changes in total cholesterol was examined by standard blood chemistry. | Baseline to Day 168 | |
Secondary | Change in HDL Cholesterol | Changes were measured in HDL cholesterol from Baseline to day 168 by standard blood chemistry. | Baseline, Day 168 | |
Secondary | Change in LDL Cholesterol | Changes in LDL Cholesterol was measured by standard blood chemistry from baseline to day 168. | Baseline, 168 days | |
Secondary | Change in Triglycerides | The change in triglycerides was evaluated by standard blood chemistry in subjects from Baseline to Day 168. | Baseline, Day 168 | |
Secondary | Change in Plasma Glucose | Change in plasma glucose was examined through standard fasting blood chemistry. | Baseline to Day 168 | |
Secondary | Change in Hemoglobin A1c (HbA1c) | Change in Hemoglobin A1c was assessed in the subjects from baseline to day 168. | Baseline, Day 168 | |
Secondary | Change in Diastolic Blood Pressure | Diastolic blood pressure was measured by standard blood pressure monitor. | Baseline to Day 168 | |
Secondary | Change in Systolic Blood Pressure | Change in Systolic blood pressure was assessed in patients from baseline to Day 168 | Baseline, Day 168 | |
Secondary | Change in Inflammatory Markers | hs-C-Reactive Protein (CRP) levels was examined by standard blood chemistry. | Baseline to Day 168 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |